Médecine

Paramédical

Autres domaines


S'abonner

Immune checkpoint inhibitor–related dermatologic adverse events - 10/10/20

Doi : 10.1016/j.jaad.2020.03.132 
Amaris N. Geisler, BS a, Gregory S. Phillips, BS b, Dulce M. Barrios, MS a, Jennifer Wu, MD c, Donald Y.M. Leung, MD, PhD d, Andrea P. Moy, MD e, Jeffrey A. Kern, MD d, Mario E. Lacouture, MD a, f,
a Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 
b State University of New York Downstate Health Sciences University, Brooklyn, New York 
c Chang Gung Memorial Hospital Linkou, Chang Gung University School of Medicine, Taoyuan, Taiwan 
d Division of Pediatric Allergy and Immunology, Department of Pediatrics, National Jewish Health, Denver, Colorado 
e Department of Pathology, Memorial Sloan Kettering Cancer, New York, New York 
f Weill Cornell Medicine, New York, New York 

Reprint requests: Mario E. Lacouture, MD, Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E 74th St, New York NY 10021.Dermatology ServiceDepartment of MedicineMemorial Sloan Kettering Cancer Center530 E 74th StNew YorkNY10021

Abstract

Immune checkpoint inhibitors have emerged as a pillar in the management of advanced malignancies. However, nonspecific immune activation may lead to immune-related adverse events, wherein the skin and its appendages are the most frequent targets. Cutaneous immune-related adverse events include a diverse group of inflammatory reactions, with maculopapular rash, pruritus, psoriasiform and lichenoid eruptions being the most prevalent subtypes. Cutaneous immune-related adverse events occur early, with maculopapular rash presenting within the first 6 weeks after the initial immune checkpoint inhibitor dose. Management involves the use of topical corticosteroids for mild to moderate (grades 1-2) rash, addition of systemic corticosteroids for severe (grade 3) rash, and discontinuation of immunotherapy with grade 4 rash. Bullous pemphigoid eruptions, vitiligo-like skin hypopigmentation/depigmentation, and psoriasiform rash are more often attributed to programmed cell death-1/programmed cell death ligand-1 inhibitors. The treatment of bullous pemphigoid eruptions is similar to the treatment of maculopapular rash and lichenoid eruptions, with the addition of rituximab in grade 3-4 rash. Skin hypopigmentation/depigmentation does not require specific dermatologic treatment aside from photoprotective measures. In addition to topical corticosteroids, psoriasiform rash may be managed with vitamin D3 analogues, narrowband ultraviolet B light phototherapy, retinoids, or immunomodulatory biologic agents. Stevens–Johnson syndrome and other severe cutaneous immune-related adverse events, although rare, have also been associated with checkpoint blockade and require inpatient care as well as urgent dermatology consultation.

Le texte complet de cet article est disponible en PDF.

Key words : checkpoint inhibitor, CTLA-4 inhibitor, dermatologic adverse event, immune-related cutaneous adverse event, lichenoid eruption, maculopapular rash, PD-1 inhibitor, PD-L1 inhibitor, pruritus, vitiligo

Abbreviations used : AE, BP, BSA, CPI, CTLA-4, DIF, DRESS, irAE, irCAE, LP, MPR, PD-1, PD-L1, SCAR, SJS, TCS, TEN


Plan


 Supported by National Cancer Institute Cancer Center support grant P30 CA008748 and National Institute of Arthritis and Musculoskeletal and Skin Diseases grant U01AR07751 (to Drs Lacouture and Leung).
 Conflicts of interest: Dr Kern has scientific advisory board roles with Oncimmune and Biodesix and consultant roles with Uptake Medical and Cireca. Dr Lacouture has consultant/speaking roles with ADC Therapeutics America, Inc, Apricity Health, LLC, Azitra, Inc, Deciphera, Johnson and Johnson, NCODA, Novocure Inc, Kyowa Kirin, Inc, Janssen Research and Development LLC, Menlo Therapeutics, Novartis Pharmaceuticals Corp, QED Therapeutics, F. Hoffmann-La Roche AG, Amgen Inc, Astrazeneca Pharmaceuticals LP, Genentech Inc, Seattle Genetics, Lutris, Paxman Coolers, Teva Mexico, Parexel, OnQuality Pharmaceuticals Ltd, Oncodermatology, and Takeda Millenium and receives research funding from Lutris, Paxman, Novocure Inc, US Biotest, and Veloce. Ms Geisler, Mr Phillips, Ms Barrios, and Drs Wu, Leung, and Moy have no conflicts of interest to disclose.
 Date of release: November 2020
 Expiration date: November 2023


© 2020  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 83 - N° 5

P. 1255-1268 - novembre 2020 Retour au numéro
Article précédent Article précédent
  • CME examination
| Article suivant Article suivant
  • Answers to CME examination

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.